Rafutrombopag is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to GlobalData, Phase III drugs for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rafutrombopag’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rafutrombopag overview

Heltrombopag Ethanolamine (Hetrombopag Ethanolamine, Herombopag Olamineu) acts by targets, binds to and stimulates the transmembrane domain of the platelet TPO-R, a member of the hematopoietin receptor superfamily. It is formulated as tablets for the oral route of administration. Herombopag Olamineu is indicated in the treatment of chronic primary immune thrombocytopenia that has not responded well to glucocorticoids, immunoglobulins, etc. in the past and has an increased risk of bleeding due to thrombocytopenia and clinical conditions and adult patients with severe aplastic anemia (SAA) refractory to immunosuppressive therapy.

Hetrombopag olamine (SHR-8735 olamine) is under development for the treatment of chemotherapy-induced thrombocytopenia (CIT), idiopathic thrombocytopenic purpura (ITP), pediatric or juvenile idiopathic thrombocytopenic purpura (ITP), aplastic anemia and chronic primary immune thrombocytopenia. The drug candidate is administered orally. It acts by targeting the thrombopoietin receptor.

Jiangsu Hengrui Medicine overview

Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

For a complete picture of Rafutrombopag’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.